Additional file 1: of Predictors of discontinuation, efficacy, and safety of memantine treatment for Alzheimer’s disease: meta-analysis and meta-regression of 18 randomized clinical trials involving 5004 patients

Additional file 1: of Pharmacodynamics of atabecestat (JNJ-54861911), an oral BACE1 inhibitor in patients with early Alzheimer’s disease: randomized, double-blind, placebo-controlled study

Maarten Timmers (3106278)
Johannes Streffer (328683)
Alberto Russu (5677178)
Yushin Tominaga (5677181)
Hiroko Shimizu (410429)
Ayako Shiraishi (5677187)
Kanaka Tatikola (5677193)
Pascale Smekens (5677202)
Anne Börjesson-Hanson (5677208)
Niels Andreasen (371679)
Jorge Matias-Guiu (5572439)
Miquel Baquero (459523)
Mercè Boada (3429242)
Ina Tesseur (511242)
Luc Tritsmans (446680)
Luc Van Nueten (3568682)
Sebastiaan Engelborghs (3523691)

August 2018

Figure S1. Four-step screening process targeting biomarker-positive patients either as preclinical A...

Additional file 1: of Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimerâs disease: study protocol for a randomised controlled trial (ELAD study)

Grazia Femminella (6553430)
Eleni Frangou (6553433)
Sharon Love (6245381)
Gail Busza (6553436)
Clive Holmes (237359)
Craig Ritchie (3531092)
Robert Lawrence (229647)
Brady McFarlane (6553439)
George Tadros (6553442)
Basil Ridha (6553445)
Carol Bannister (6553448)
Zuzana Walker (573075)
Hilary Archer (6553451)
Elizabeth Coulthard (6553454)
Ben Underwood (6553457)
Aparna Prasanna (6553460)
Paul Koranteng (6553463)
Salman Karim (6553466)
Kehinde Junaid (6553469)
Bernadette McGuinness (237354)
Ramin Nilforooshan (5172128)
Ajay Macharouthu (6553472)
Andrew Donaldson (6553475)
Simon Thacker (6553478)
Gregor Russell (6553481)
Naghma Malik (6553484)
Vandana Mate (6553487)
Lucy Knight (6553490)
Sajeev Kshemendran (6553493)
John Harrison (3512513)
David Brooks (5369636)
Anthony Passmore (6553496)
Clive Ballard (89605)
Paul Edison (6398009)

April 2019

SPIRIT 2013 checklist: items addressed in the clinical trial protocol. (DOC 121 kb

Additional file 1: of Reducing disability via a family centered intervention for acutely ill persons with Alzheimerâs disease and related dementias: protocol of a cluster-randomized controlled trial (Fam-FFC study)

Marie Boltz (5755031)
Ashley Kuzmik (5755034)
Barbara Resnick (5755037)
Rebecca Trotta (5755043)
Jacqueline Mogle (5755046)
Rhonda BeLue (4962424)
Douglas Leslie (5755049)
James Galvin (5755052)

September 2018

Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) 2013 Checklist. (PDF 175...

Additional file 3: of Predictors of discontinuation, efficacy, and safety of memantine treatment for Alzheimer’s disease: meta-analysis and meta-regression of 18 randomized clinical trials involving 5004 patients

Lídia Blanco-Silvente (5555627)
Dolors Capellà (352935)
Josep Garre-Olmo (3706405)
Joan Vilalta-Franch (4923337)
Xavier Castells (34190)

July 2018

Characteristics of included clinical trials. We provide the references of included studies (Table S1...

Additional file 6: of Predictors of discontinuation, efficacy, and safety of memantine treatment for Alzheimer’s disease: meta-analysis and meta-regression of 18 randomized clinical trials involving 5004 patients

Lídia Blanco-Silvente (5555627)
Dolors Capellà (352935)
Josep Garre-Olmo (3706405)
Joan Vilalta-Franch (4923337)
Xavier Castells (34190)

July 2018

Sensitivity analyses and publication bias. We provide the results of the two sensitivity analyses: b...

Additional file 4: of Predictors of discontinuation, efficacy, and safety of memantine treatment for Alzheimer’s disease: meta-analysis and meta-regression of 18 randomized clinical trials involving 5004 patients

Lídia Blanco-Silvente (5555627)
Dolors Capellà (352935)
Josep Garre-Olmo (3706405)
Joan Vilalta-Franch (4923337)
Xavier Castells (34190)

July 2018

Risk of bias of included clinical trials. We provide the risk of bias of included studies on differe...

Additional file 1: of Comparative safety and effectiveness of cholinesterase inhibitors and memantine for Alzheimerâs disease: a network meta-analysis of 41 randomized controlled trials

Kai-Xin Dou (6161522)
Meng-Shan Tan (6161525)
Chen-Chen Tan (523854)
Xi-Peng Cao (5206148)
Xiao-He Hou (6161528)
Qi-Hao Guo (6161531)
Lan Tan (477054)
Vincent Mok (397930)
Jin-Tai Yu (477053)

December 2018

Supplementary 1. Network meta-analysis model. Supplementary 2. References for included trials. Suppl...

Additional file 2: of Prevalence and risk of progression of preclinical Alzheimer’s disease stages: a systematic review and meta-analysis

Lucilla Parnetti (120805)
Elena Chipi (6211280)
Nicola Salvadori (4283104)
Katia D’Andrea (6211286)
Paolo Eusebi (432118)

January 2019

Table S2. Cut-offs used for defining pre-clinical Alzheimer’s disease according biomarkers positivit...

Additional file 1: of Data-driven identification of endophenotypes of Alzheimerâs disease progression: implications for clinical trials and therapeutic interventions

Nophar Geifman (492428)
Richard Kennedy (248483)
Lon Schneider (4799259)
Iain Buchan (379469)
Roberta Brinton (4799262)

January 2018

Full list of drug groups and search terms used to evaluate medication use at baseline (XLSX 42 kb

Additional file 2: of Bapineuzumab for mild to moderate Alzheimerâs disease: a meta-analysis of randomized controlled trials

Abdelrahman Abushouk (3904879)
Ahmed Elmaraezy (3500438)
Amro Aglan (3904891)
Reham Salama (3904894)
Samar Fouda (3904882)
Rana Fouda (3904885)
Ammar AlSafadi (3904888)

April 2017

Shows the authorsâ judgements for risk of bias assessment domains with supporting reasons. (DOCX 2...

Additional file 1: of Safety and tolerability of donepezil 23 mg with or without intermediate dose titration in patients with Alzheimer’s disease taking donepezil 10 mg: a multicenter, randomized, open-label, parallel-design, three-arm, prospective trial

Yun Hong (572033)
Hyun Han (6652223)
Young Youn (4689577)
Kyung Park (3454454)
Dong Yang (141041)
SangYun Kim (431184)
Hwa Kim (3470603)
Ji Kim (3527534)
Jae-Hong Lee (1645459)

May 2019

Table S1. Baseline demographics and clinical characteristics of the subjects (per protocol populatio...

Additional file 2: of Bapineuzumab for mild to moderate Alzheimerâs disease in two global, randomized, phase 3 trials

Rik Vandenberghe (674079)
Juha Rinne (3429236)
MercĂ¨ Boada (3429254)
Sadao Katayama (3429221)
Philip Scheltens (142045)
Bruno Vellas (133953)
Michael Tuchman (3429227)
Achim Gass (539278)
Jochen Fiebach (3429218)
Derek Hill (3429203)
Kasia Lobello (3429245)
David Li (194538)
Tom McRae (3429230)
Prisca Lucas (3429212)
Iona Evans (3429239)
Kevin Booth (3429224)
Gerald Luscan (3429209)
Bradley Wyman (3429233)
Lisa Hua (3429251)
Lingfeng Yang (3429206)
H. Brashear (3429248)
Ronald Black (3429215)

May 2016

Inclusion and exclusion criteria. Inclusion and exclusion criteria, similar to those used in the 301...

Data_Sheet_1_Meta-Analysis of Randomized Controlled Trials on the Efficacy and Safety of Donepezil, Galantamine, Rivastigmine, and Memantine for the Treatment of Alzheimer’s Disease.PDF

Dan-Dan Li (137178)
Ya-Hong Zhang (2343091)
Wei Zhang (405)
Pu Zhao (444209)

May 2019

To study the impact of donepezil, rivastigmine, galantamine, and memantine on cognitive, functional,...

Additional file 1: of Motivational processes in mild cognitive impairment and Alzheimer’s disease: results from the Motivational Reserve in Alzheimer’s (MoReA) study

Simon Forstmeier (3501044)
Andreas Maercker (371401)

November 2015

STROBE Statement—Checklist of items that should be included in reports of cohort studies. (PDF 28 kb

Additional file 1: of FUNDAMANT: an interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimerâs disease

Petr Novak (109770)
Reinhold Schmidt (33935)
Eva Kontsekova (5894363)
Branislav Kovacech (5894366)
Tomas Smolek (5894369)
Stanislav Katina (849475)
Lubica Fialova (5894372)
Michal Prcina (5894375)
Vojtech Parrak (5894378)
Peter Dal-Bianco (292140)
Martin Brunner (805199)
Wolfgang Staffen (5894381)
Michael Rainer (5894384)
Matej Ondrus (5894387)
Stefan Ropele (310902)
Miroslav Smisek (5894390)
Roman Sivak (5894393)
Norbert Zilka (5894396)
Bengt Winblad (281202)
Michal Novak (3945095)

October 2018

Supplementary material for FUNDAMANT: An interventional 72-week phase 1 follow study of AADvac1, an ...

Additional file 1: of Pharmacodynamics of atabecestat (JNJ-54861911), an oral BACE1 inhibitor in patients with early Alzheimer’s disease: randomized, double-blind, placebo-controlled study

Maarten Timmers (3106278)
Johannes Streffer (328683)
Alberto Russu (5677178)
Yushin Tominaga (5677181)
Hiroko Shimizu (410429)
Ayako Shiraishi (5677187)
Kanaka Tatikola (5677193)
Pascale Smekens (5677202)
Anne Börjesson-Hanson (5677208)
Niels Andreasen (371679)
Jorge Matias-Guiu (5572439)
Miquel Baquero (459523)
Mercè Boada (3429242)
Ina Tesseur (511242)
Luc Tritsmans (446680)
Luc Van Nueten (3568682)
Sebastiaan Engelborghs (3523691)

August 2018

Figure S1. Four-step screening process targeting biomarker-positive patients either as preclinical A...

Additional file 1: of Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimerâs disease: study protocol for a randomised controlled trial (ELAD study)

Grazia Femminella (6553430)
Eleni Frangou (6553433)
Sharon Love (6245381)
Gail Busza (6553436)
Clive Holmes (237359)
Craig Ritchie (3531092)
Robert Lawrence (229647)
Brady McFarlane (6553439)
George Tadros (6553442)
Basil Ridha (6553445)
Carol Bannister (6553448)
Zuzana Walker (573075)
Hilary Archer (6553451)
Elizabeth Coulthard (6553454)
Ben Underwood (6553457)
Aparna Prasanna (6553460)
Paul Koranteng (6553463)
Salman Karim (6553466)
Kehinde Junaid (6553469)
Bernadette McGuinness (237354)
Ramin Nilforooshan (5172128)
Ajay Macharouthu (6553472)
Andrew Donaldson (6553475)
Simon Thacker (6553478)
Gregor Russell (6553481)
Naghma Malik (6553484)
Vandana Mate (6553487)
Lucy Knight (6553490)
Sajeev Kshemendran (6553493)
John Harrison (3512513)
David Brooks (5369636)
Anthony Passmore (6553496)
Clive Ballard (89605)
Paul Edison (6398009)

April 2019

SPIRIT 2013 checklist: items addressed in the clinical trial protocol. (DOC 121 kb

Additional file 1: of Reducing disability via a family centered intervention for acutely ill persons with Alzheimerâs disease and related dementias: protocol of a cluster-randomized controlled trial (Fam-FFC study)

Marie Boltz (5755031)
Ashley Kuzmik (5755034)
Barbara Resnick (5755037)
Rebecca Trotta (5755043)
Jacqueline Mogle (5755046)
Rhonda BeLue (4962424)
Douglas Leslie (5755049)
James Galvin (5755052)

September 2018

Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) 2013 Checklist. (PDF 175...

Additional file 3: of Predictors of discontinuation, efficacy, and safety of memantine treatment for Alzheimer’s disease: meta-analysis and meta-regression of 18 randomized clinical trials involving 5004 patients

Lídia Blanco-Silvente (5555627)
Dolors Capellà (352935)
Josep Garre-Olmo (3706405)
Joan Vilalta-Franch (4923337)
Xavier Castells (34190)

July 2018

Characteristics of included clinical trials. We provide the references of included studies (Table S1...

Additional file 6: of Predictors of discontinuation, efficacy, and safety of memantine treatment for Alzheimer’s disease: meta-analysis and meta-regression of 18 randomized clinical trials involving 5004 patients

Lídia Blanco-Silvente (5555627)
Dolors Capellà (352935)
Josep Garre-Olmo (3706405)
Joan Vilalta-Franch (4923337)
Xavier Castells (34190)

July 2018

Sensitivity analyses and publication bias. We provide the results of the two sensitivity analyses: b...

Additional file 4: of Predictors of discontinuation, efficacy, and safety of memantine treatment for Alzheimer’s disease: meta-analysis and meta-regression of 18 randomized clinical trials involving 5004 patients

Lídia Blanco-Silvente (5555627)
Dolors Capellà (352935)
Josep Garre-Olmo (3706405)
Joan Vilalta-Franch (4923337)
Xavier Castells (34190)

July 2018

Risk of bias of included clinical trials. We provide the risk of bias of included studies on differe...

Additional file 1: of Comparative safety and effectiveness of cholinesterase inhibitors and memantine for Alzheimerâs disease: a network meta-analysis of 41 randomized controlled trials

Kai-Xin Dou (6161522)
Meng-Shan Tan (6161525)
Chen-Chen Tan (523854)
Xi-Peng Cao (5206148)
Xiao-He Hou (6161528)
Qi-Hao Guo (6161531)
Lan Tan (477054)
Vincent Mok (397930)
Jin-Tai Yu (477053)

December 2018

Supplementary 1. Network meta-analysis model. Supplementary 2. References for included trials. Suppl...

Additional file 2: of Prevalence and risk of progression of preclinical Alzheimer’s disease stages: a systematic review and meta-analysis

Lucilla Parnetti (120805)
Elena Chipi (6211280)
Nicola Salvadori (4283104)
Katia D’Andrea (6211286)
Paolo Eusebi (432118)

January 2019

Table S2. Cut-offs used for defining pre-clinical Alzheimer’s disease according biomarkers positivit...

Additional file 1: of Data-driven identification of endophenotypes of Alzheimerâs disease progression: implications for clinical trials and therapeutic interventions

Nophar Geifman (492428)
Richard Kennedy (248483)
Lon Schneider (4799259)
Iain Buchan (379469)
Roberta Brinton (4799262)

January 2018

Full list of drug groups and search terms used to evaluate medication use at baseline (XLSX 42 kb

Additional file 2: of Bapineuzumab for mild to moderate Alzheimerâs disease: a meta-analysis of randomized controlled trials

Abdelrahman Abushouk (3904879)
Ahmed Elmaraezy (3500438)
Amro Aglan (3904891)
Reham Salama (3904894)
Samar Fouda (3904882)
Rana Fouda (3904885)
Ammar AlSafadi (3904888)

April 2017

Shows the authorsâ judgements for risk of bias assessment domains with supporting reasons. (DOCX 2...

Additional file 1: of Safety and tolerability of donepezil 23 mg with or without intermediate dose titration in patients with Alzheimer’s disease taking donepezil 10 mg: a multicenter, randomized, open-label, parallel-design, three-arm, prospective trial

Yun Hong (572033)
Hyun Han (6652223)
Young Youn (4689577)
Kyung Park (3454454)
Dong Yang (141041)
SangYun Kim (431184)
Hwa Kim (3470603)
Ji Kim (3527534)
Jae-Hong Lee (1645459)

May 2019

Table S1. Baseline demographics and clinical characteristics of the subjects (per protocol populatio...

Additional file 2: of Bapineuzumab for mild to moderate Alzheimerâs disease in two global, randomized, phase 3 trials

Rik Vandenberghe (674079)
Juha Rinne (3429236)
MercĂ¨ Boada (3429254)
Sadao Katayama (3429221)
Philip Scheltens (142045)
Bruno Vellas (133953)
Michael Tuchman (3429227)
Achim Gass (539278)
Jochen Fiebach (3429218)
Derek Hill (3429203)
Kasia Lobello (3429245)
David Li (194538)
Tom McRae (3429230)
Prisca Lucas (3429212)
Iona Evans (3429239)
Kevin Booth (3429224)
Gerald Luscan (3429209)
Bradley Wyman (3429233)
Lisa Hua (3429251)
Lingfeng Yang (3429206)
H. Brashear (3429248)
Ronald Black (3429215)

May 2016

Inclusion and exclusion criteria. Inclusion and exclusion criteria, similar to those used in the 301...

Data_Sheet_1_Meta-Analysis of Randomized Controlled Trials on the Efficacy and Safety of Donepezil, Galantamine, Rivastigmine, and Memantine for the Treatment of Alzheimer’s Disease.PDF

Dan-Dan Li (137178)
Ya-Hong Zhang (2343091)
Wei Zhang (405)
Pu Zhao (444209)

May 2019

To study the impact of donepezil, rivastigmine, galantamine, and memantine on cognitive, functional,...

Additional file 1: of Motivational processes in mild cognitive impairment and Alzheimer’s disease: results from the Motivational Reserve in Alzheimer’s (MoReA) study

Simon Forstmeier (3501044)
Andreas Maercker (371401)

November 2015

STROBE Statement—Checklist of items that should be included in reports of cohort studies. (PDF 28 kb

Additional file 1: of FUNDAMANT: an interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimerâs disease

Petr Novak (109770)
Reinhold Schmidt (33935)
Eva Kontsekova (5894363)
Branislav Kovacech (5894366)
Tomas Smolek (5894369)
Stanislav Katina (849475)
Lubica Fialova (5894372)
Michal Prcina (5894375)
Vojtech Parrak (5894378)
Peter Dal-Bianco (292140)
Martin Brunner (805199)
Wolfgang Staffen (5894381)
Michael Rainer (5894384)
Matej Ondrus (5894387)
Stefan Ropele (310902)
Miroslav Smisek (5894390)
Roman Sivak (5894393)
Norbert Zilka (5894396)
Bengt Winblad (281202)
Michal Novak (3945095)

October 2018

Supplementary material for FUNDAMANT: An interventional 72-week phase 1 follow study of AADvac1, an ...

Additional file 1: of Pharmacodynamics of atabecestat (JNJ-54861911), an oral BACE1 inhibitor in patients with early Alzheimer’s disease: randomized, double-blind, placebo-controlled study

Maarten Timmers (3106278)
Johannes Streffer (328683)
Alberto Russu (5677178)
Yushin Tominaga (5677181)
Hiroko Shimizu (410429)
Ayako Shiraishi (5677187)
Kanaka Tatikola (5677193)
Pascale Smekens (5677202)
Anne Börjesson-Hanson (5677208)
Niels Andreasen (371679)
Jorge Matias-Guiu (5572439)
Miquel Baquero (459523)
Mercè Boada (3429242)
Ina Tesseur (511242)
Luc Tritsmans (446680)
Luc Van Nueten (3568682)
Sebastiaan Engelborghs (3523691)

August 2018

Figure S1. Four-step screening process targeting biomarker-positive patients either as preclinical A...

Additional file 1: of Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimerâs disease: study protocol for a randomised controlled trial (ELAD study)

Grazia Femminella (6553430)
Eleni Frangou (6553433)
Sharon Love (6245381)
Gail Busza (6553436)
Clive Holmes (237359)
Craig Ritchie (3531092)
Robert Lawrence (229647)
Brady McFarlane (6553439)
George Tadros (6553442)
Basil Ridha (6553445)
Carol Bannister (6553448)
Zuzana Walker (573075)
Hilary Archer (6553451)
Elizabeth Coulthard (6553454)
Ben Underwood (6553457)
Aparna Prasanna (6553460)
Paul Koranteng (6553463)
Salman Karim (6553466)
Kehinde Junaid (6553469)
Bernadette McGuinness (237354)
Ramin Nilforooshan (5172128)
Ajay Macharouthu (6553472)
Andrew Donaldson (6553475)
Simon Thacker (6553478)
Gregor Russell (6553481)
Naghma Malik (6553484)
Vandana Mate (6553487)
Lucy Knight (6553490)
Sajeev Kshemendran (6553493)
John Harrison (3512513)
David Brooks (5369636)
Anthony Passmore (6553496)
Clive Ballard (89605)
Paul Edison (6398009)

April 2019

SPIRIT 2013 checklist: items addressed in the clinical trial protocol. (DOC 121 kb

Additional file 1: of Reducing disability via a family centered intervention for acutely ill persons with Alzheimerâs disease and related dementias: protocol of a cluster-randomized controlled trial (Fam-FFC study)

Marie Boltz (5755031)
Ashley Kuzmik (5755034)
Barbara Resnick (5755037)
Rebecca Trotta (5755043)
Jacqueline Mogle (5755046)
Rhonda BeLue (4962424)
Douglas Leslie (5755049)
James Galvin (5755052)

September 2018

Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) 2013 Checklist. (PDF 175...

Additional file 1: of Predictors of discontinuation, efficacy, and safety of memantine treatment for Alzheimer’s disease: meta-analysis and meta-regression of 18 randomized clinical trials involving 5004 patients

Abstract

Extracted data

Additional file 1: of Predictors of discontinuation, efficacy, and safety of memantine treatment for Alzheimer’s disease: meta-analysis and meta-regression of 18 randomized clinical trials involving 5004 patients

Abstract

Extracted data

Related items

Related items